---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-25-000029"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:51:03.671573+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Black Diamond completes Phase 2 enrollment for silevertinib; net loss narrows to $10.6M

## Summary
- Cash $142.8M (vs $98.6M Dec 2024) funds operations into Q4 2027.
- Net loss $10.6M in Q2 2025 vs $19.9M in Q2 2024; R&D expenses down to $9.3M.
- Phase 2 trial of silevertinib in 1L non-classical EGFRm NSCLC fully enrolled (n=43); ORR & preliminary DOR data expected Q4 2025.
- Exploring partnership opportunities for silevertinib in NSCLC and GBM; FDA meeting planned for 1H 2026 on registrational path.

## SEC filing metadata
- accession: 0001701541-25-000029
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154125000029/0001701541-25-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154125000029/bdtx-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-25-000029
- JSON: https://secwatch.observer/filing/0001701541-25-000029.json
- Plain text: https://secwatch.observer/filing/0001701541-25-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.